When researchers at ACR Convergence 2024 presented positive data from the RESET RA study regarding vagus nerve stimulation in rheumatoid arthritis, it represented the latest milestone on a long and unpredictable journey for the treatment.
It’s a journey that, according to those researchers and other experts, will likely end in FDA approval for RA, possibly as early as this year.